Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany.
Institute of Experimental and Clinical Pharmacology, University Hospital of Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany.
J Mol Med (Berl). 2021 Aug;99(8):1073-1083. doi: 10.1007/s00109-021-02065-3. Epub 2021 Apr 16.
The present study elucidates the neuroprotective mechanisms of the PPARγ (peroxisome proliferator-activated receptor γ) agonist pioglitazone in survival of ischemic neurons following middle cerebral artery occlusion with reperfusion (MCAO). Intracerebroventricular infusion of pioglitazone over 5 days before and 24 or 48 h after MCAO alleviated neurological impairments, inhibited apoptosis 24 h, and activated the PI3K/Akt pathway along with increased phosphorylation of Akt (ser473) and GSK-3β (ser9) in the peri-infarct cortical areas 48 h after MCAO. In primary cortical neurons, pioglitazone suppressed the glutamate-induced release of lactate dehydrogenase by a PPARγ-dependent mechanism. This protective effect was reversed after co-treatment with PI3K and Akt inhibitors, LY294002 and SH-6, respectively. Pioglitazone enhanced the expression of the antioxidative transcription factor Nrf2 and its target gene protein, heme oxidase-1, in the peri-infarct area. Pioglitazone also increased activation of the antioxidant response element (ARE) in neuronal PC12 cells transfected with the pNQO1-rARE plasmid. We demonstrate in primary cortical neurons from Nrf2 knockout mice that the lack of Nrf2 completely abolished the neuroprotective effects of pioglitazone against oxidative and excitotoxic damage. Our results strongly suggest that the neuroprotective effects of PPARγ in peri-infarct brain tissues comprise the concomitant activation of the PI3K/Akt and Nrf2/ARE pathways. KEY MESSAGES: Pioglitazone inhibits apoptosis in ischemic brain tissue. Pioglitazone acting on PPARγ activates PI3K/Akt pathway in ischemic brain tissue. Pioglitazone activates via Nrf2 the antioxidant defense pathway in injured neurons. Pioglitazone activates the antioxidant response element in neuronal PC12 cells. Pioglitazone fails to protect primary neurons lacking Nrf2 against oxidative damage. Activation of PPARγ supports the survival of viable neurons in peri-infarct regions.
本研究阐明了过氧化物酶体增殖物激活受体γ(PPARγ)激动剂吡格列酮在大脑中动脉闭塞再灌注后(MCAO)缺血神经元存活中的神经保护机制。MCAO 前 5 天和 24 或 48 小时内脑室内输注吡格列酮可减轻神经损伤,抑制 24 小时凋亡,并在 MCAO 后 48 小时激活 PI3K/Akt 通路,同时增加 Akt(ser473)和 GSK-3β(ser9)在梗死周围皮质区的磷酸化。在原代皮质神经元中,吡格列酮通过 PPARγ 依赖机制抑制谷氨酸诱导的乳酸脱氢酶释放。这种保护作用在与 PI3K 和 Akt 抑制剂 LY294002 和 SH-6 共同处理后被逆转。吡格列酮增强了 Nrf2 及其靶基因蛋白血红素加氧酶-1在梗死周围区域的抗氧化转录因子的表达。吡格列酮还增加了转染 pNQO1-rARE 质粒的神经元 PC12 细胞中抗氧化反应元件(ARE)的激活。我们在 Nrf2 基因敲除小鼠的原代皮质神经元中证明,Nrf2 的缺失完全消除了吡格列酮对氧化和兴奋毒性损伤的神经保护作用。我们的研究结果强烈表明,PPARγ 在梗死周围脑组织中的神经保护作用包括同时激活 PI3K/Akt 和 Nrf2/ARE 通路。关键信息:吡格列酮抑制缺血脑组织中的细胞凋亡。吡格列酮作用于 PPARγ 可激活缺血脑组织中的 PI3K/Akt 通路。吡格列酮通过 Nrf2 激活受损神经元中的抗氧化防御途径。吡格列酮激活神经元 PC12 细胞中的抗氧化反应元件。缺乏 Nrf2 的原代神经元无法抵抗氧化损伤而得到吡格列酮的保护。激活 PPARγ 支持存活的神经元在梗死周围区域的存活。